temozolomide has been researched along with capecitabine in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (5.88) | 29.6817 |
| 2010's | 46 (54.12) | 24.3611 |
| 2020's | 34 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
| Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E | 1 |
| Bruce, JN; Fine, RL; Freda, PU; Isaacson, SR; Lee, Y; Thearle, MS | 1 |
| Eriksson, B | 1 |
| Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK | 1 |
| Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR | 1 |
| Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S | 1 |
| Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T | 1 |
| Claringbold, PG; Price, RA; Turner, JH | 1 |
| Fine, RL; Gulati, AP; Krantz, B; Moss, RA; Mowatt, KB; Moyal, WN; Schreibman, S; Tsushima, DA | 1 |
| Enk, AH; Gronau, M; Hassel, JC; Jäger, D | 1 |
| Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J | 1 |
| Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA | 1 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
| Bruce, JN; Carminucci, AS; Fine, RL; Gulati, AP; Lignelli, A; Remotti, H; Siegelin, M; Wardlaw, SL; Zacharia, BE | 1 |
| Saif, MW; Tejani, MA | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Cao, KI; Kirova, YM | 1 |
| Sands, MJ; Wunderle, KA | 1 |
| Abbasi, S; Albaba, H; Kashashna, A | 1 |
| Lok, E; Swanson, KD; Wong, ET | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Claringbold, PG; Turner, JH | 1 |
| Backen, A; Barriuso, J; Elliott, E; Hubner, R; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Beyer, DT; Boudreaux, JP; Chauhan, A; Ramirez, RA; Wang, YZ; Woltering, EA | 1 |
| Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M | 1 |
| Kesavan, M; Turner, JH | 1 |
| Hong, YS; Jeong, JH; Kim, J; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Park, JH; Park, Y; Yu, CS | 1 |
| Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J | 1 |
| Arnal, AV; Donovan, LE; Odia, Y; Wang, SH | 1 |
| Aller, J; Alonso, V; Alonso-Gordoa, T; Barriuso, J; Capdevila, J; Carmona-Bayonas, A; Crespo, G; Custodio, A; Gajate, P; Grande, E; Jiménez-Fonseca, P; López, C; Matos, I; Navarro, M; Nieto, B; Sevilla, I | 1 |
| An, C; He, X; Hua, X; Kong, X; Liu, X; Matkar, S; Wang, L; Xie, G | 1 |
| Carilli, A; Pellini Ferreira, B; Vasquez, J | 1 |
| Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J | 1 |
| Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P | 1 |
| Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D | 1 |
| Fu, W; Li, W; Lu, L; Lu, Y; Lv, W; Wang, J; Zhao, Z | 1 |
| Amoroso, V; Berruti, A; Bertani, E; Cella, CA; Fazio, N; Laffi, A; Maisonneuve, P; Pellicori, S; Pozzari, M; Spada, F | 1 |
| Brizzi, MP; Di Maio, M; La Salvia, A; Muratori, L; Scagliotti, GV; Trevisi, E | 1 |
| Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Gorzelak, A; Iżycka-Świeszewska, E; Kos-Kudła, B; Lebiedzińska, A; Rogowski, W; Sulżyc-Bielicka, V; Wachuła, E; Żołnierek, J | 1 |
| Ahmadzadehfar, H; Ahrens, H; Brossart, P; Essler, M; Feldmann, G; Fottner, C; Gaertner, FC; Miederer, M; Schreckenberger, M; Weber, MM; Yordanova, A | 1 |
| Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Joseph, R; Mathews, S; McRee, AJ; Zeidner, JF | 1 |
| Alexandraki, KI; Angelousi, A; Chatzellis, E; Daskalakis, K; Gross, D; Grozinsky-Glasberg, S; Kaltsas, G; Kos-Kudła, B; Koumarianou, A; Maimon, O; Meirovitz, A; Tsoli, M; Wachuła, E | 1 |
| Backen, A; Kordatou, Z; Lamarca, A; Mansoor, W; McCallum, L; Nasralla, M; Nonaka, D; Papaxoinis, G | 1 |
| Al-Toubah, T; Morse, B; Strosberg, J | 2 |
| Barriuso, J; Hubner, RA; Lamarca, A; Manoharan, P; Mansoor, W; McNamara, MG; Valle, JW | 1 |
| Alexandraki, KI; Angelousi, A; Chatzellis, E; Daskalakis, K; Gross, D; Grozinsky-Glasberg, S; Kaltsas, G; Kos-Kudła, B; Koumarianou, A; Maimon, O; Meirovitz, A; Tsoli, M; Wachula, E | 1 |
| Antista, M; Barault, L; Corallo, S; de Braud, F; Di Bartolomeo, M; Di Maio, M; Di Nicolantonio, F; Farina, G; Fucà, G; Gori, S; Guarini, V; Lobefaro, R; Lonardi, S; Longarini, R; Macagno, M; Martinetti, A; Milione, M; Morano, F; Mosconi, S; Murgioni, S; Pagani, F; Palermo, F; Perrone, F; Petrelli, F; Pietrantonio, F; Raimondi, A; Randon, G; Rimassa, L; Sartore-Bianchi, A; Tamborini, E; Tomasello, G | 1 |
| Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ | 1 |
| Couto, J; Marques, B; Martins, RG; Monteiro, AR; Ribeiro, J; Rodrigues, F | 1 |
| Bergquist, JR; Chang, EM; Dua, MM; Li, AY; Scott, GD; Visser, BC | 1 |
| Caraglia, M; Ottaiano, A | 1 |
| Pagani, F; Pietrantonio, F; Randon, G | 1 |
| Chen, J; Jin, KZ; Li, YL; Liang, Y; Peng, Y; Tan, HY; Wang, W; Yu, XJ; Zhang, Y; Zhou, ZW | 1 |
| Antonuzzo, L; Barberis, M; Campana, D; Faviana, P; Fazio, N; Fumagalli, C; Gelsomino, F; Maisonneuve, P; Marconcini, R; Messerini, L; Puliafito, I; Rossi, G; Spada, F | 1 |
| Chik, CL; Easaw, J; Inoshita, N; Mehta, V; Nakano-Tateno, T; Satou, M; Tateno, T; van Landeghem, FKH | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
| Basu, S; Bhandare, MS; Bhargava, P; Chaudhari, V; Ostwal, V; Parghane, RV; Ramaswamy, A; Shah, M; Shrikhande, SV; Srinivas, S | 1 |
| Guo, Y; Li, D; Li, Z; Su, W; Wang, Y | 1 |
| Bongiovanni, A; Calpona, S; Cocchi, C; De Vita, A; Di Menna, G; Fausti, V; Foca, F; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Riva, N; Spadazzi, C | 1 |
| Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J | 1 |
| Araki, T; Kawakami, Y; Lau, KJ; McMahon, C; Nakano-Tateno, T; Tateno, T; Wang, J | 1 |
| Claringbold, PG; Grover, P; Kesavan, M; Lam, WS; Turner, JH | 1 |
| Colao, A; Faggiano, A; Ferraù, F; Lania, A; Modica, R; Rubino, M | 1 |
| Al-Toubah, T; Haider, M; Pelle, E; Strosberg, JR; Valone, T | 1 |
| Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W | 1 |
| Fukuoka, H; Inoshita, N; Ishida, A; Ogawa, W; Shichi, H; Yamada, S | 1 |
| Aubanell, A; Biagetti, B; Capdevila, J; Chaachou, A; Filippi-Arriaga, F; Garcia-Alvarez, A; Hernandez Hernandez, I; Hernando, J; Martínez-Saez, E; Mirallas, O | 1 |
| Dong, J; Gao, H; Li, H; Liu, L; Wang, W; Xu, H; Ye, L; Yu, X; Zhang, W | 1 |
| Dogan, I; Karabulut, S; Sakar, B; Tastekin, D | 1 |
| Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM | 1 |
| Baek, JY; Beom, SH; Cha, Y; Choi, J; Choi, MK; Hong, YS; Kim, J; Kim, JE; Kim, JH; Kim, SY; Kim, TW; Lee, JS; Lim, SB; Oh, CR; Park, IJ; Park, JH | 1 |
| Badesha, J; Boutin, M; Farnell, D; Gill, S; Loree, JM; Mathews, A; Paul, A; Safro, M; Schaeffer, D; Stuart, HC | 1 |
| Chatterjee, D; Itani, M; Navale, P; Trikalinos, NA | 1 |
| Ağdaş, G; Ak, N; Akay, B; Akyıldız, A; Alan, Ö; Arak, H; Aydınalp, Y; Azizy, A; Bayram, D; Bilgin, B; Büyükbayram, ME; Büyükşimşek, M; Çağlayan, M; Canaslan, K; Çetin, B; Çoban, E; Demirci, A; Derin, S; Dursun, B; Ercelep, Ö; Erdal, GŞ; Eryılmaz, MK; Evrensel, T; Göksu, SS; Gümüş, M; Güven, DC; Güzel, HG; Hendem, E; Kahvecioğlu, FA; Kalkan, Z; Karabulut, S; Karataş, F; Kefeli, U; Kılıçkap, S; Köş, FT; Ön, S; Ordu, Ç; Oruç, Z; Özçelik, M; Özdemir, N; Paksoy, N; Paydaş, S; Sağlam, S; Sakin, A; Salim, DK; Şanlı, UA; Selvi, O; Şendur, MAN; Sever, N; Seyyar, M; Şimşek, M; Taştekin, D; Tatlı, AM; Topçu, A; Turna, ZH; Uğraklı, M; Ünal, Ç; Ünek, İT; Ürün, Y; Uygun, K; Yalçın, Ş; Yaşar, S; Yazıcı, O; Yücel, KB | 1 |
14 review(s) available for temozolomide and capecitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2a; Prognosis; Review Literature as Topic; Temozolomide; Tomography, X-Ray Computed | 2013 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Octreotide; Temozolomide; Thalidomide | 2015 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Neuroendocrine Tumors; Radiopharmaceuticals; Somatostatin; Streptozocin; Temozolomide | 2016 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide | 2016 |
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Observational Studies as Topic; Survival Analysis; Temozolomide | 2018 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Humans; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Sunitinib; Temozolomide; Vascular Endothelial Growth Factor A | 2018 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Topics: Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Dopamine Agonists; Humans; Pituitary Neoplasms; Temozolomide; Treatment Outcome | 2021 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Radioisotopes; Somatostatin; Temozolomide; Treatment Outcome | 2021 |
10 trial(s) available for temozolomide and capecitabine
| Article | Year |
|---|---|
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Nausea; Temozolomide; Treatment Outcome; Vomiting | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabine; Cyclooxygenase 2 Inhibitors; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Edema; Efferent Pathways; Erythema; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Immunohistochemistry; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pioglitazone; PPAR gamma; Predictive Value of Tests; Quality of Life; Sulfones; Temozolomide; Thiazolidinediones; Treatment Outcome | 2007 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Temozolomide; Treatment Outcome | 2012 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarbazine; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Preoperative Care; Rectal Neoplasms; Temozolomide; Treatment Outcome; Vomiting | 2016 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Quality of Life; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2020 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2021 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DNA; DNA Methylation; DNA Repair Enzymes; Glioblastoma; Humans; Prospective Studies; Rectal Neoplasms; Temozolomide | 2023 |
61 other study(ies) available for temozolomide and capecitabine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Radiography; Temozolomide; Treatment Outcome | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dacarbazine; Deoxycytidine; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Male; Paraganglioma; Retroperitoneal Neoplasms; Succinate Dehydrogenase; Temozolomide; Treatment Outcome | 2012 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neuroendocrine; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Necrolytic Migratory Erythema; Neoplasm Staging; Pancreatic Neoplasms; Paraneoplastic Syndromes; Risk Assessment; Temozolomide; Treatment Outcome | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thymus Neoplasms; Treatment Outcome | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary ACTH Hypersecretion; Temozolomide | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Radiation recall after a transarterial hepatic chemoembolization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Chemoembolization, Therapeutic; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Fluoroscopy; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Radiodermatitis; Radiography, Interventional; Risk Factors; Temozolomide; Time Factors | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Thioguanine; Treatment Failure | 2015 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Temozolomide | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co-Repressor Proteins; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Molecular Chaperones; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Telomere; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; X-linked Nuclear Protein | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Dacarbazine; Everolimus; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Pituitary Neoplasms; Protein Serine-Threonine Kinases; Temozolomide | 2016 |
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Proportional Hazards Models; Spain; Survival Analysis; Temozolomide; Treatment Outcome | 2017 |
BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Benzodiazepines; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dacarbazine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Protein Stability; RNA, Messenger; S-Phase Kinase-Associated Proteins; Temozolomide; Transcription Factors; Transcriptional Activation; Ubiquitin-Protein Ligases; Ubiquitination; Up-Regulation | 2017 |
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Carcinoma, Hepatocellular; Dacarbazine; Glucagon; Glucagonoma; Humans; Jaundice; Liver; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Temozolomide; Treatment Outcome | 2017 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution | 2018 |
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes | 2018 |
Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Neuroendocrine Tumors; Temozolomide; Treatment Outcome | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide | 2019 |
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2019 |
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Temozolomide | 2019 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide | 2020 |
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chromosome Inversion; Chromosomes, Human, Pair 16; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Neuroendocrine Tumors; Palliative Care; Prognosis; Temozolomide | 2019 |
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2019 |
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Female; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Outcome Assessment, Health Care; Prognosis; Retrospective Studies; Temozolomide | 2020 |
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Temozolomide; Treatment Outcome | 2020 |
Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.
Topics: Capecitabine; Duration of Therapy; Fluorouracil; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ
Topics: Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Registries; Retrospective Studies; Temozolomide; Time Factors; United States | 2020 |
Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Insulin; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peptides, Cyclic; Remission Induction; Secretory Pathway; Somatostatin; Temozolomide; Treatment Outcome; Vipoma | 2020 |
Nearing the Summit: Associating Liver Partitioning and Portal Ligation for Staged Hepatectomy (ALPPS) in Progressive Carcinoid Disease.
Topics: Antineoplastic Agents; Capecitabine; Disease Progression; Female; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Regeneration; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2020 |
MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Letter.
Topics: Capecitabine; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2020 |
MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response.
Topics: Capecitabine; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2020 |
A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Outcome Assessment, Health Care; Prognosis; Retrospective Studies; Temozolomide; Young Adult | 2021 |
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Corticotrophs; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide | 2021 |
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Temozolomide | 2021 |
Evaluation of hepatic drug-metabolism for glioblastoma using liver-brain chip.
Topics: Astrocytes; Blood-Brain Barrier; Brain; Capecitabine; Coculture Techniques; Endothelial Cells; Glioblastoma; Hep G2 Cells; Humans; Inactivation, Metabolic; Lab-On-A-Chip Devices; Liver; Nanoparticles; Paclitaxel; Temozolomide | 2021 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Outcome Assessment, Health Care; Temozolomide | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Sunitinib; Temozolomide | 2022 |
Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
Topics: Capecitabine; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2022 |
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Male; Middle Aged; Nelson Syndrome; Neoplasm Invasiveness; Pituitary Neoplasms; Spain; Temozolomide; Treatment Outcome; Tumor Burden | 2021 |
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Retrospective Studies; Temozolomide | 2022 |
The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Prospective Studies; Retrospective Studies; Temozolomide | 2022 |
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Retrospective Studies; Temozolomide; Treatment Outcome | 2022 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tuberous Sclerosis | 2023 |
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Temozolomide; Treatment Outcome; Turkey | 2023 |